Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 17;3(4):1490-510.
doi: 10.3390/jcm3041490.

The Use of Patient-Specific Induced Pluripotent Stem Cells (iPSCs) to Identify Osteoclast Defects in Rare Genetic Bone Disorders

I-Ping Chen  1
Affiliations

The Use of Patient-Specific Induced Pluripotent Stem Cells (iPSCs) to Identify Osteoclast Defects in Rare Genetic Bone Disorders

I-Ping Chen. J Clin Med. .

Abstract

More than 500 rare genetic bone disorders have been described, but for many of them only limited treatment options are available. Challenges for studying these bone diseases come from a lack of suitable animal models and unavailability of skeletal tissues for studies. Effectors for skeletal abnormalities of bone disorders may be abnormal bone formation directed by osteoblasts or anomalous bone resorption by osteoclasts, or both. Patient-specific induced pluripotent stem cells (iPSCs) can be generated from somatic cells of various tissue sources and in theory can be differentiated into any desired cell type. However, successful differentiation of hiPSCs into functional bone cells is still a challenge. Our group focuses on the use of human iPSCs (hiPSCs) to identify osteoclast defects in craniometaphyseal dysplasia. In this review, we describe the impact of stem cell technology on research for better treatment of such disorders, the generation of hiPSCs from patients with rare genetic bone disorders and current protocols for differentiating hiPSCs into osteoclasts.

Keywords: induced pluripotent stem cells; osteoclast; rare genetic bone disorders.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of generating osteoclasts from human iPSCs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kornak U., Mundlos S. Genetic disorders of the skeleton: A developmental approach. Am. J. Hum. Genet. 2003;73:447–474. doi: 10.1086/377110. - DOI - PMC - PubMed
    1. Chen I.P., Wang C.J., Strecker S., Koczon-Jaremko B., Boskey A., Reichenberger E.J. Introduction of a Phe377del mutation in ANK creates a mouse model for craniometaphyseal dysplasia. J. Bone Miner. Res. 2009;24:1206–1215. doi: 10.1359/jbmr.090218. - DOI - PMC - PubMed
    1. Chen I.P., Wang L., Jiang X., Aguila H.L., Reichenberger E.J. A Phe377del mutation in ANK leads to impaired osteoblastogenesis and osteoclastogenesis in a mouse model for craniometaphyseal dysplasia (CMD) Hum. Mol. Genet. 2011;20:948–961. doi: 10.1093/hmg/ddq541. - DOI - PMC - PubMed
    1. Laslo P., Spooner C.J., Warmflash A., Lancki D.W., Lee H.J., Sciammas R., Gantner B.N., Dinner A.R., Singh H. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell. 2006;126:755–766. doi: 10.1016/j.cell.2006.06.052. - DOI - PubMed
    1. Kawaguchi N., Noda M. Mitf is expressed in osteoclast progenitors in vitro. Exp. Cell Res. 2000;260:284–291. doi: 10.1006/excr.2000.5020. - DOI - PubMed

LinkOut - more resources